Table 1.
CMR value for sudden cardiac death risk stratification in patients with hypertrophic cardiomyopathy.
| Imaging Parameter | Clinical Evidence Supporting Assessment for SCD Risk Stratification | CMR Advantages over Echocardiography |
|---|---|---|
| MLVWT * | ++++ | +++ |
| LGE (extent) * | ++++ | ++++ |
| LVEF * | +++ | +++ |
| LV aneurysm * | +++ | ++ |
| Maximum LVOT Gradient * | +++ | - |
| LA size * | +++ | ++ |
| LV strain | ++ | +/− |
| LV mass | + | ++++ |
| Extracellular Volume | + | ++++ |
| Native T1 mapping | +/− | ++++ |
| Native T2 mapping | - | ++++ |
| Right Ventricular Involvement | +/− | +++ |
| LA function | - | +/− |
- Absent; +/− Doubtful; + Weak; ++ Moderate; +++ Strong; ++++ Very Strong. CMR: cardiac magnetic resonance; LA: left atrium; LGE: late gadolinium enhancement; LV: left ventricle; LVEF: left ventricular ejection fraction; LVOT: left ventricular outflow tract; MLVWT: maximum left ventricular wall thickness; SCD: sudden cardiac death. * Included in international guidelines for clinical management of patients with hypertrophic cardiomyopathy.